Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atrial Fibrillation?: The ATRIA Study

Circulation. Cardiovascular quality and outcomes- United States

doi 10.1161/circoutcomes.108.830232

Full Text

Abstract

Available in

Date

Authors

Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Duration of Nonvalvular Atrial Fibrillation and Stroke.

Stroke
CardiologyNeurologyCardiovascular MedicineAdvancedMedicineNeuroscienceSpecialized Nursing
1983English

Suboptimal Anticoagulant Management in Japanese Patients With Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention

Journal of Stroke and Cerebrovascular Diseases
SurgeryNeurologyCardiovascular MedicineRehabilitationCardiology
2017English

Novel Anticoagulants for Thromboembolic Complications Prevention in Nonvalvular Atrial Fibrillation

Russian Journal of Cardiology
Cardiovascular MedicineCardiology
2015English

Stroke Prevention in Atrial Fibrillation

Journal of Atrial Fibrillation
Cardiovascular MedicineCardiology
2010English

Stroke Prevention in Atrial Fibrillation

International Journal of Arrhythmia
2017English

Personalizing Bridging Anticoagulation in Patients With Nonvalvular Atrial Fibrillation—a Microsimulation Analysis

Journal of General Internal Medicine
Internal Medicine
2017English

Stroke Prevention in Atrial Fibrillation Trial

Circulation
Cardiovascular MedicinePhysiologyCardiology
1991English

Cost-Effectiveness Analysis of Apixaban Against Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation in Japan

Clinical Therapeutics
Pharmacology
2015English

Left Atrial Appendage Exclusion for Stroke Prevention in Atrial Fibrillation

Cardiology Research and Practice
Cardiovascular MedicineCardiology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy